Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy
Author:
Yan Xu,Wensi Li,Gang An,Weiwei Sui,Shuhui Deng,Tingyu Wang,Shuhua Yi,Wenyang Huang,Wei Liu,Qi Wang,Rui Lv,Wenjie Xiong,Chenxing Du,Judy Zhu,Jiaqi Huang,Chengxiao Zheng,Liping Lan,Kevin Zhu,Lugui Qiu,Dehui Zou
Copyright © 2023 The American Society of Hematology. Published by Elsevier Inc. All rights reserved.